+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06917573

Phase II Study of Cemiplimab With or Without Chemotherapy Based on ctDNA Response in Advanced Non-Small Cell Lung Cancer Patients

Led by Fundación GECP · Updated on 2025-11-19

63

Participants Needed

20

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting an open-label, non-randomised phase II clinical trial to study patients with stage IV or stage IIIBC non-small cell lung cancer NSCLC who are not candidates for definitive chemotherapy, radiotherapy, or surgery. The trial aims to determine if therapy decisions guided by circulating tumor DNA ctDNA analysis can improve overall survival in patients who have not received prior systemic anti-cancer therapy. Participants will initially receive two cycles of Cemiplimab, given by intravenous infusion every 28 days. After evaluating their response and ctDNA levels, they will either continue with Cemiplimab alone or receive Cemiplimab combined with chemotherapy. Chemotherapy options include Carboplatin with Pemetrexed or Carboplatin with taxanes, selected by the investigator. Treatment with Cemiplimab can continue up to two years unless disease progresses or unacceptable side effects occur. Throughout the trial, patients will be closely monitored with imaging to assess tumor response and ctDNA measurements. Researchers will track overall survival as the primary outcome over 24 months following the initial treatment cycles. Secondary outcomes include progression-free survival, sites of first failure, and duration of response. The study includes a treatment period of about two years plus two years of follow-up, with total participation lasting approximately six and a half years.

CONDITIONS

Brief Title

PALACE: Cemiplimab Trial According to ctDNA Levels

Research Team

E

Eva Pereira

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here